Core Points - The Global Vaccine Alliance (Gavi) successfully raised over $9 billion for the next five years (2026-2030) during the "Immunization for Health and Prosperity" summit in Brussels, despite a significant decline in global health financing [1][3] - Gavi has provided vaccines to over 1 billion children since its inception in 2000, preventing more than 18 million avoidable deaths, and currently serves nearly half of the world's children [1][3] - The UK and the Bill & Melinda Gates Foundation are the largest contributors, with the UK pledging £1.25 billion (approximately $1.6 billion) and the Gates Foundation contributing $1.6 billion [3] - The U.S. has historically been a significant donor, contributing around $300 million annually, but announced it would stop funding Gavi, which could impact global vaccination efforts [3][4] Funding and Contributions - The total commitments for the next five years include £1.25 billion from the UK, $1.6 billion from the Gates Foundation, and over €360 million from the European Commission and member states, totaling over €2 billion [3] - Indonesia, which recently graduated from Gavi's support list, pledged $30 million for the next five years, showcasing a shift from recipient to donor [5] Gavi's Operational Model - Gavi operates on a co-financing model where even low-income countries contribute a small amount per vaccine dose, gradually increasing their financial responsibility as their economies grow [5] - Gavi's CEO, Sania Nishtar, emphasized the importance of maintaining communication with the U.S. government to secure ongoing support [5] China's Role - China is highlighted as a successful example of Gavi's empowerment model, transitioning from a recipient to a donor, contributing over $120 million since 2016 [7] - The collaboration between China and Gavi began in 2002 with a hepatitis B vaccination program, significantly increasing vaccination rates in impoverished regions [7][8] Vaccine Development and Innovation - Gavi is focusing on expanding its vaccine portfolio, including support for vaccines against hepatitis E, tuberculosis, and monkeypox, as part of its 6.0 vaccine investment strategy [8][9] - Gavi is interested in innovative delivery methods, such as microneedle patches, to improve vaccine accessibility in low-resource settings [9][10] Leadership and Vision - Sania Nishtar, the first CEO from a developing country, brings a unique perspective to Gavi, having witnessed the impact of vaccine-preventable diseases firsthand [12][13] - Nishtar's background as a physician and public health advocate informs her commitment to ensuring health and immunization as fundamental human rights [13]

智通财经APP获悉，4月21日，全球领先的疫苗合同定制研发和生产（CDMO）服务公司药明海德宣布 与全球领先的创新细菌疫苗研发企业羽冠生物达成战略合作。羽冠生物将借助药明海德在疫苗CDMO领 域的一体化研发和生产服务能力以及世界一流的质量体系，推广其新一代细菌外囊泡技术平台OMV Plus在全球细菌疫苗领域的广泛应用。双方将共同推动细菌疫苗创新，为全球公共卫生健康事业做出贡 献。 作为最具潜力的新一代细菌疫苗技术之一，工程化OMV疫苗有效解决了细菌疫苗抗原种类繁多、筛选 复杂的技术挑战，具有无需额外添加佐剂即可增强保护效力的优势，其商业化应用已获得验证。羽冠生 物OMV Plus平台成功突破了传统OMV疫苗的多个技术瓶颈，大幅提高了OMV产量和广谱性，可支持几 乎所有革兰氏阴性菌疫苗的开发。 羽冠生物创始人兼CEO林秋彬博士表示，非常高兴与药明海德深化合作，共同推动创新细菌疫苗技术的 全球应用。在过去的12个月中，双方团队齐心协力、开拓创新，以行业加速度证明了羽冠生物疫苗创新 的实力。借助药明海德在疫苗CMC和生产领域的精深知识和丰富经验，公司成功实现了中国首个B群脑 膜炎球菌OMV疫苗的规模化生产，并且显著 ...